Piper Jaffray analyst Matt O'Brien says he spoke to Integra LifeSciences after the company disclosed a warning letter relating to its wound care manufacturing facility in Boston. The company emphasized that there were no safety issues associated with the products, O'Brien tells investors in a research note. The analyst does not expect the letter to impact revenue much, if at all. Management believes that it will be able to have the issue resolved within about six months, he adds. These FDA warnings letters happen, and is "not the end of the world" for Integra's wound care business, says O'Brien. He keeps an Overweight rating on Integra LifeSciences with a $62 price target.

BTIG notes that seven Medicare Administrative Contractors, or MACs - CGS, WPS, NGS, Palmetto, Novitas, First Coast, and Noridian - this morning published new proposed local coverage determinations, or LCDs, regarding the coverage of skin substitutes grafts and cellular and tissue based products for the treatment of diabetic foot ulcers, or DFUs, and venous leg ulcers, or VLUs. This marks "the second attempt in the past 12 months where MACs have proposed an LCD that would drastically shake up the advanced wound care market," says the analyst, who highlights that the proposed LCD includes non-coverage products from Integra Lifesciences (IART), Organogenesis (ORGO), Smith & Nephew (SNN), MiMedx (MDXG), Anika Therapeutics (ANIK) and numerous smaller, private wound care companies. The firm adds that it thinks Integra and Organogenesis both have meaningful exposure to the LCDs based on their product portfolio and the revenue mix within their Advanced Wound Care businesses.